Summary. The membrane complex a IIb b 3 is the major receptor for fibrinogen and is involved in platelet adhesion and aggregation. Evidence has been presented that the Pl A2 allele of the b 3 Pl A1/A2 gene polymorphism might be an independent risk factor for coronary thrombosis, but the matter is still controversial. We investigated the relationship between this polymorphism and possible alterations of platelet functions in vitro. The platelet adhesion to fibrinogen-coated microplate wells and the aggregation induced by several different agonists were tested in 63 healthy volunteers, among them, 49 subjects with Pl A1/A1 polymorphism, 12 subjects with Pl A1/A2 polymorphism and two subjects with Pl A2/A2 polymorphism. Subjects with Pl
The membrane integrin complex a IIb b 3 (glycoprotein IIb/ IIIa) is a major receptor for platelet adhesion and aggregation. The gene encoding the subunit b 3 is polymorphic at exon 2 (position 1565). The more common allele encodes a leucine (Pl A1 ) and the less common allele encodes a proline (Pl A2 ). A high frequency of family members homozygous for Pl A2 was found in kindreds with a high prevalence of acute coronary diseases under 60 years of age (Weiss et al, 1995) . The same authors later reported an association between acute coronary thrombosis and Pl A2 polymorphism (Weiss et al, 1996) . These papers generated great interest and have given rise to various reports on this and related matters, some of which support the original findings (Carter et al, 1997; Walter et al, 1997; Zotz et al, 1998; Garcia-Ribes et al, 1998; Pastinen et al, 1998; Kastrati et al, 1999; and some of which do not (Hato et al, 1997; Herrmann et al, 1997; Ridker et al, 1997; Samani & Lodwick, 1997; Durante-Mangoni et al, 1998; Garg et al, 1998; Mamotte et al, 1998; Scaglione et al, 1998; Sperr et al, 1998; Laule et al, 1999) . Recently, Gardemann et al (1998) established an association between Pl A2 polymorphism and coronary disease in a large population. However, they did not find a relationship between this genotype and myocardial infarction. This polymorphism was also investigated in relation to stroke and conflicting results have also been reported (Carlsson et al, 1997; Carter et al, 1998; Wagner et al, 1998) .
Even though there is strong evidence that the complex a IIb b 3 has a primary role in the pathogenesis of acute coronary syndromes (Kleiman et al, 1998) , the role of the Pl A2 polymorphism as a thrombotic risk factor is undefined and the mechanism(s) whereby this polymorphism could lead to an increased risk of thrombosis is unknown. To date, there is little evidence of an association of Pl A2 with molecular markers of abnormal haemostasis: an association between this polymorphism and higher plasma Lp(a) concentration (Joven et al, 1998) , and a reduced plasma fibrinogen concentration (Senti et al, 1998) compared with Pl A1 subjects have been reported. This may indicate that this polymorphism plays a role in platelet post-activation events, possibly leading to increased binding of fibrinogen (Goodall et al, 1999) . However, this hypothesis appears to be negated by the finding of no effect on fibrinogen binding (Meiklejohn et al, 1999) or decreased fibrinogen binding to Pl A2 platelets (Weiss et al, 1997) . Investigations of the possible effects of the Pl A1/A2 polymorphism on human platelet function in vitro have reported contradictory results : Feng et al (1999) described an increased aggregability of the Pl A2 platelets to epinephrine and ADP, whereas Corral et al (1997) No data have been published on the possible effect of Pl A1/ A2 genotypes on platelet adhesion, one of the earlier events by which platelets perform their functions in the haemostatic process. Therefore, further investigations are required to investigate the relationship between this polymorphism of the fibrinogen receptor and the various functions of platelets that can be assessed in vitro.
The objective of the present report was to evaluate possible modifications of platelet adhesion to fibrinogen and of aggregation, using stimulants that act through different activation pathways, in subjects with different Pl A alleles. The starting hypothesis was that the presence of the Pl
A2
allele was associated with a tendency to higher basal (resting) adhesion and/or higher responsiveness to agonists. We have tested this hypothesis in a well defined group of healthy volunteers.
PATIENTS AND METHODS

Subjects.
A total of 63 healthy volunteers (35 men and 28 women), all non-smokers, aged from 25 years to 62 years, were studied. The participants had not taken any drugs for at least 3 weeks and were carefully interviewed at the time they donated blood to exclude known risk factors affecting platelet function and/or platelet dysfunction. All volunteers participating in this study had given their informed, written consent, according to Italian law. Blood samples were collected after overnight fasting and without venous occlusion, to avoid stasis and anoxia.
For the purpose of the Pl A genotyping, 4 ml of venous blood was collected into EDTA-containing vacutainer tubes. DNA was extracted from whole blood using a standard extraction protocol (Sambrook et al, 1989) . Pl A genotypes were determined as previously described (Weiss et al, 1996) . The sense oligonucleotide primer was 5 H -TGGACTTCTCTTTGGGCTCCTGACTTAC-3 H and the antisense primer was 5 H -CGATGGATTCTGGGGCACAGTTATC-3 (Osborn et al, 1996) . Template DNA was amplified in a final volume of 100 ml containing 20 pmol of each primer, 200 mmol/l of each dNTP, 2 U of Taq polymerase (Bioline), 50 mmol/l KCl, 1´5 mmol/l MgCl 2 and 10 mmol/l Tris-HCl (pH 8´3). After initial denaturation at 958C for 2 min, amplification of DNA was performed in a thermal cycler (Perkin Elmer Cetus) for 39 cycles (denaturation: 2 min at 958C; annealing: 1 min at 588C; extension: 2 min at 728C). Amplified DNA was digested by 20 U MspI (16 h at 378C). The digested products of the Pl A1 and Pl
A2
alleles were electrophoresed in 4% agarose gels and visualized by ethidium bromide staining. As the negative internal control, the polymerase chain reaction (PCR) procedure was also performed utilizing amplification products in samples containing no genomic DNA. The results of the genotyping assay were analysed by at least two investigators who were unaware of the origin of the DNA. Whenever there was any ambiguity in PCR, MspI digestion and scoring were repeated. Platelet isolation and in vitro functional testing. For the aggregation and adhesion tests, platelets were harvested from blood by differential centrifugation (Andrioli et al, 1999) and utilized within 1 h. A final volume of 20 ml of blood was drawn by venepuncture in 3´32 ml of anticoagulant solution (11´8 mmol/l citric acid, 18 mmol/l dextrose, 14 mmol/l sodium citrate) and platelet-rich plasma was obtained by centrifugation at 300 g for 10 min. The platelet-rich plasma was recentrifuged at 700 g for 15 min and platelets were gently suspended (2 Â 10 8 platelets/ml for aggregation test and 5 Â 10 7 platelets/ml for adhesion test) in a buffer composed of 145 mmol/l NaCl, 5 mmol/l KCl, 10 mmol/l HEPES, 0´5 mmol/l Na 2 HPO 4 , 6 mmol/l glucose and 0´2% human serum albumin, pH 7´4 (buffer A). The platelet suspensions were kept at room temperature and utilized within 1 h. Ten minutes before use, platelets were warmed to 378C. A colorimetric procedure measuring the activity of acid phosphatase was used for the determination of the adhesion of human platelets to fibrinogen-coated culture microplates (Bellavite et al, 1994) . Briefly, 96-well microtitre plates were coated overnight with 0´2 mg/ml human fibrinogen (Sigma Chemical Company) in phosphate-buffered saline (PBS) and washed twice with physiological saline. Immediately after coating and washing, the wells were supplemented with 25 ml of buffer A containing 3 mmol/l CaCl 2 and 3 mmol/l of MgSO 4 (for assay of unstimulated cells) or with 25 ml of the tested agonists (final concentrations: 3 mmol/l ADP, 0´02 U/ml thrombin, 5 mmol/l arachidonic acid, 100 nmol/l U46619, a thromboxane A 2 analogue) in buffer A containing 3 mmol/l CaCl 2 and 3 mmol/l MgSO 4 . Plates were then warmed to 378C and 50 ml of the platelet suspension (2´5 Â 10 6 platelets), prewarmed to 378C, was added to each well. The incubation was carried out for 60 min and plates were then subjected to two washing cycles with PBS at room temperature. After washing, the wells containing adherent platelets were rapidly supplemented with 150 ml of 100 mmol/l citrate buffer, pH 5´4, containing 5 mmol/l p-nitrophenyl-phosphate and 0´1% Triton X-100. After incubation at room temperature for 60 min, the reaction was stopped and the colour was developed by the addition of 100 ml/well of 2 N NaOH. The p-nitrophenol produced by the reaction was measured with a microplate reader (Reader 400, SLT Labs Instruments) at 405 nm against a platelet-free blank. The percentage of adherent cells was calculated on the basis of a standard curve obtained with a defined number of platelets from the same donor.
The rate of platelet aggregation was measured according to Born (1962) by using a four-channel aggregometer (Aggrecorder II PA-3220, Daiichi). Suspensions of washed platelets (0´5 ml, 10 8 platelets) were warmed in the aggregometer at 378C for 1 min in buffer A, in the presence of 1 mmol/l CaCl 2 and 1 mmol/l MgSO 4 , with continuous stirring at 1000 r.p.m. The rate of platelet aggregation was monitored for 3 min after the addition of the agonists (10 mmol/l ADP, 0´06 U/ml thrombin, 1 mmol/l U-46619 and 15 mmol/l arachidonic acid) and was expressed as the percentage change of transmitted light.
Flow cytometry. Measurements of the expression of CD41 (complex a IIb b 3 ) and CD62P (GMP-140) in the platelets were performed by fluorescence-activated flow cytometry, as previously described (Andrioli et al, 1996) . Immediately after collection, whole blood samples were diluted with cold (48C) buffer A (2´5 Â 10 5 platelets/ml) and incubated with saturating concentrations of either anti-human CD41 monoclonal antibody (mAb) conjugated with fluoroscein isothiocyanate (FITC) and anti-human CD62P mAb (phycoerythrin, PE) or fluoresceinated and phycoerythrinated control immunoglobulin G 1 mAbs (Immunotech). The anti-human CD41 mAb is produced from clone P2 (hybridoma SP2/O-Ag.14 myeloma X Balb/C spleen cells) and reacts with the subunits a IIb and b 3 in complexinhibiting platelet aggregation induced by thrombin, collagen and ADP. The anti-human CD62P mAb is produced from clone CLB-thromb/6 (hybridoma SP2/O Â Ag 1´4 Â Balb/c Â AJ spleen cells) and recognizes the GMP-140 expressed on the activated platelets. Incubation with mAbs was carried out for 20 min at 48C. This temperature was selected on the basis of preliminary experiments showing a minimal platelet activation under this condition (percentage of CD62P 1 platelets with incubation at 48C: 3´8^0´9; percentage of CD62P 1 platelets with incubation at room temperature: 5´4^1´1; n 6). Finally, the Statistical analysis. The Mann±Whitney rank sum test was used for the analysis of non-parametrically distributed data. The statistical analysis was performed using a computer program (sigmastat 2´0, SPSS). Data were expressed as means^SD. Statistical significance and the IC 50 were calculated by a computer program (graphpad inplot). P , 0´05 was considered statistically significant.
RESULTS
Population characteristics
Sixty-three subjects, 35 men and 28 women, with a mean age of 47 years (range 25±62 years), were studied. In this group, we found 49 subjects with Pl A1/A1 polymorphism (77´8%), 12 subjects with Pl A1/A2 polymorphism (19%) and two subjects with Pl A2/A2 polymorphism (3´2%). Owing to the small number of Pl A2/A2 subjects, they were grouped together with the Pl A1/A2 subjects and all these 14 subjects are referred to as Pl A2 subjects. The most relevant characteristics of the volunteers and their plasma parameters are summarized in Table I . As shown, no significant differences were observed between the Pl A1 and Pl
A2
subjects. Metabolic indices and body mass were remarkably similar in the two groups. There was a difference in sex distribution. However, platelet activation did not differ between men and women in both groups. The clinical interviews and these baseline parameters excluded the presence in our studied subjects of the most known cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidaemia, increased plasma fibrinogen levels) associated with modified platelet activity.
Platelet adhesion and aggregation
The platelet adhesion on fibrinogen in the resting state and after different stimuli was tested in vitro under static conditions. We found no differences between the Pl A1 and the Pl A2 genotypes in resting adhesion and after 3 mmol/l ADP or 0´02 U/ml thrombin stimulation (Table II) . On the other hand, using 5 mmol/l arachidonic acid or 100 nmol/l U46619 as agonists, the Pl A2 platelets showed a significantly reduced adhesion compared with the Pl A1 platelets. Platelet aggregation (Table II) was also performed with different stimuli: 0´06 U/ml thrombin, 10 mmol ADP, 15 mmol arachidonic acid and 1 mmol U46619. No differences were found between Pl A1 and Pl A2 platelet aggregation using thrombin or ADP as stimulants. Pl A2 platelets aggregated with a significantly reduced rate when compared with Pl A1 platelets using arachidonic acid or U46619.
The results of aggregation tests in response to arachidonic acid and to U46619 performed in each donor are reported in Fig 1. Two Pl A2 subjects were non-responders to arachidonic acid and to U46619, and four Pl A2 subjects were markedly low-responders (, 30% aggregation). There was a good correspondence in the aggregation responses to the two different agonists in the different individuals, with the exception of one Pl A1/A1 subject, whose platelets showed Effects of acetylsalicylic acid on arachidonic acid-induced platelet aggrgegation. After the incubation for 15 min of the platelet suspensions with scalar doses of acetylsalicylic acid, the aggregation test was performed as described in the Patients and methods section, using 15 mmol/l arachidonic acid. This series of assays included eight randomly chosen Pl A1 subjects (W) and the eight Pl A2 subjects (X) who showed normal or borderline responses to arachidonic acid in the absence of acetylsalicylic acid (subjects 4, 18, 21, 26, 28, 35, 37, 48 in Fig 1) . Data are expressed as means^SD.
a very low response to arachidonic acid (12%) and a normal response to U46619. Subjects numbers 12 and 61 were homozygous for the Pl A2 allele; probably because of the small number of subjects, this analysis did not discriminate Pl A1/A2 from Pl A2/A2 platelets. Figure 1 also shows that six out of seven subjects with markedly defective aggregation by arachidonic acid and six out of six subjects with markedly defective aggregation by U46619 belonged to the Pl A2 group.
Sensitivity of Pl
A1 and Pl A2 platelets to acetylsalicylic acid To investigate the contribution of the endogenous generation of thromboxane A 2 in subjects with different Pl A1 and Pl A2 polymorphisms, platelet aggregation in response to arachidonic acid was tested after incubation with increasing doses of acetylsalicylic acid. For technical reasons, this comparison could be performed only in Pl A1 and Pl A2 subjects that showed normal or near normal aggregation. Therefore, the six Pl A2 subjects with markedly reduced (, 30%) aggregation responses were excluded from this series of experiments. Dose±effect curves (Fig 2) showed that Pl A2 platelets are significantly more sensitive to inhibition by acetylsalicylic acid than Pl A1 platelets. The concentration of the drug able to reduce the aggregation response by 50% was 2´7^0´6 mmol/l and 23´4^3´3 mmol/l for Pl A2 and Pl A1 platelets respectively (P , 0´005). platelets with respect to Pl A1 platelets ex vivo, we studied the CD41 and CD62P expression on platelet membranes and determined the plasma b-thromboglobulin levels of Pl A2 vs. Pl A1 groups. The expression of the selected platelet antigens did not differ significantly in the two groups (% of CD41 1 platelets: Pl A1 68^4, Pl A2 70^5, NS; % of CD62P 1 platelets: Pl A1 : 4^1%, Pl A2 : 5^2, NS). There was also no difference between the plasma b-thromboglobulin levels of the two groups (Pl A1 26´5^1´8 ng/ml Pl A2 subject 29´2^2´2 ng/ml p NS).
DISCUSSION
Integrins containing a b 3 subunit include a IIb b 3 , the most abundant and functionally important integrin on platelets, and a V b 3 , which is prominently expressed on endothelial cells, monocytes/macrophages and vascular smooth muscle cells. The glycoprotein a IIb b 3 is the major fibrinogen receptor of the human platelet membrane and is activated after cell stimulation by a number of agonists, thus participating in adhesion and aggregation. The interest in this protein in clinical pathology was further increased when an association between the myocardial infarction with the Pl A2 allele of the Pl A1/A2 b 3 gene polymorphism was reported (Weiss et al, 1996) . However, the relationship between this molecular variance, cellular functions and pathological effects remains to be clarified.
The design of this in vitro study did not enable us to define whether or not the Pl A2 genotype is clinically relevant, because all the subjects of the population under study were of healthy status. However, our data may allow better understanding of the molecular pathophysiology of cardiovascular risk in relation to the Pl A phenotype. In the present study, we analysed whether b 3 genotypes have any association with two major platelet functions, i.e. adhesive and aggregative reactions. Using two different tests of platelet function and four different agonists, we provided the new finding that an abnormal platelet response to thromboxane A 2 (either exogenously or endogenously generated from arachidonic acid) exists in Pl A2 subjects. Thus, not only the hypothesis of a hyper-responsiveness of platelets as a possible mechanism for increased cardiovascular risk in these subjects was rejected, but a paradoxical defect in these cells was identified.
There are several possible explanations for the agonist specificity of such a defect. The most direct explanation points to the existence of (at least) two molecular`switches' by which b 3 integrin is involved in platelet adhesion and aggregation: one modification, involving amino acid position n 1565 at exon 2, is critical for activation directly by thromboxane A 2 and indirectly by arachidonic acid, while the Pl A polymorphism is not critical for activation by ADP and thrombin. This hypothesis is in agreement with the current knowledge indicating that different transduction pathways, proximal to the fibrinogen receptor, are utilized by different agonists (Du & Ginsberg, 1997) . According to this model, the finding of increased sensitivity to acetylsalicylic acid may simply indicate that the drug unmasks a latent defect by reducing the endogenous generation of thromboxane A 2 and, thus, the b 3 integrin modification by this pathway. However, because of the complexity of fibrinogen-receptor function, it cannot be excluded that the indicated molecular modification of b 3 integrin may affect other signalling pathways involved in cellular activation. The involvement of the fibrinogen receptor in outside-in activation or amplification of signals has been already suggested (Shattil et al, 1997) .
A possible explaination of the decrease of Pl A2 platelet response to thromboxane A 2 could be the result of a desensitization of the thromboxane A 2 receptor following activation in vivo. According to this hypothesis, the Pl A2 platelets could be activated in vivo and subsequently become hypo-responsive. However, from our data obtained by flowcytometric analysis and on determination of b-thromboglobulin plasma levels, two investigations of possible platelet activation in vivo, we did not determine any up-regulation of Pl A2 platelets with respect to Pl A1 platelets. From our data obtained by in vitro assay of platelet function and by ex vivo assessment of platelet activation markers, it seems that the suggested thrombogenic effect of the Pl A2 polymorphism (Weiss et al, 1996; Carter et al, 1997; Walter et al, 1997; Garcia-Ribes et al, 1998; Pastinen et al, 1998; Zotz et al, 1998; Kastrati et al, 1999) is not related to platelet hyper-activity. This consideration is in accordance with others authors (Lasne et al, 1997) . However, we did not observe a platelet hypo-reactivity to thrombin or ADP as described by Lasne et al (1997) . This q 2000 Blackwell Science Ltd, British Journal of Haematology 110: 911±918 discrepancy could be related to different experimental conditions (we studied washed platelets, Lasne and colleagues studied platelet-rich plasma). Basically, it cannot be excluded that the Pl A2 genotype is linked to another yet unidentified genetic marker, which is the true risk determinant, or to other platelet disorders, where a defect of the thromboxane A 2 receptor has been described (Higuchi et al, 1999) . Further studies are necessary to clarify this point. It cannot be ruled out that other cellular sources than platelets are being affected, as the b 3 subunit is part of the vitronectin receptor which is expressed in endothelial cells, smooth muscle cells and a number of other cells. As this integrin receptor (a V b 3 ) is highly involved in angiogenesis, polymorphism of glycoprotein b 3 has also to be considered in relation to the pathophysiology of cardiac vasculature. It is known that the integrin a V b 3 could mediate platelet adhesion to the activated endothelial cells (Gawaz et al, 1997) . More recently, in an animal model, an antithrombotic role for vitronectin was reported (Fay et al, 1999) . This effect seems to be mediated by inhibiting platelet±platelet interactions and/or thrombin procoagulant activity. If these data are confirmed in humans, anomalous functioning of the anti-thrombotic role of the vitronectin receptor could be advanced to explain the role of Pl A2 as a cardiovascular risk factor.
Because of the small sample size of the Pl A2 subjects considered in this work (n 14), the statistical power of the present study is low. This limitation of the study does not affect the finding of differences which are statistically significant (i.e. platelet responses to arachidonic acid and U46619). On the other hand, the negative findings (i.e. platelet responses in the resting condition or to ADP or thrombin) do not rule out the possibility that some small difference may actually exist. However, the differences between the non-significant values of the Pl A2 and Pl
A1
groups are so small that they probably do not have a relevance at the clinical level. The differences in dose±inhibition curves with acetylsalicylic acid are in accordance with a recent letter, Cooke et al (1998) , showing a greater sensitivity to acetylsalicylic acid in Pl A1/A2 platelets than in Pl A1/A1 platelets. These authors suggested that differences in exposure of patients to the drug at the time of onset of myocardial infarction might account for some of the discrepancies amongst studies on Pl A as a risk factor for ischaemic coronary events.
In conclusion, our findings are not consistent with the hypothesis that the purported increase of cardiovascular risk in these subjects may be as a result of fibrinogen receptor hyper-activation. On the contrary, the Pl A2 allele is associated with a platelet functional deficiency, specifically linked to the activation of the fibrinogen receptor by thromboxane A 2 .
